NASDAQ : ANL
Adlai Nortye Ltd. — Key statistics
Healthcare · Biotechnology · Cayman Islands
Last price 9.55 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 615.00M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 615.00M |
| Enterprise Value | 408.88M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 64.40M |
| Shares Change (YoY) | +14.47% |
| Shares Change (QoQ) | +49.29% |
| Owned by Insiders (%) | 0.93% |
| Owned by Institutions (%) | 42.88% |
| Float | 49.57M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 34.06 |
| Forward PS | 213.30 |
| PB Ratio | 2.86 |
| P/TBV Ratio | 2.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 22.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.55 |
| Quick Ratio | 9.24 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.99 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -20.23% |
| Return on Assets (ROA) | -8.70% |
| Return on Invested Capital (ROIC) | -9.48% |
| Return on Capital Employed (ROCE) | -9.99% |
| Weighted Average Cost of Capital (WACC) | 10.08% |
| Revenue Per Employee | $165,651 |
| Profits Per Employee | -$206,688 |
| Employee Count | 109 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.11 |
| 52-Week Price Change | +536.67% |
| 50-Day Moving Average | 13.82 |
| 200-Day Moving Average | 11.39 |
| Relative Strength Index (RSI) | 31.56 |
| Average Volume (20 Days) | 345,527 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.09M |
| Short Previous Month | 4.40M |
| Short % of Shares Out | 8.74% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 18.84 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 18.06M |
| Gross Profit | 18.06M |
| Operating Income | -22.29M |
| Pretax Income | -22.53M |
| Net Income | -22.53M |
| EBITDA | -21.65M |
| EBIT | -22.29M |
| Loss Per Share | -$0.56 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 232.82M |
| Total Debt | 26.70M |
| Net Cash | 206.12M |
| Net Cash Per Share | $3.20 |
| Equity (Book Value) | 214.83M |
| Book Value Per Share | 3.34 |
| Working Capital | 215.66M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -33.69M |
| Capital Expenditures | -187,000 |
| Depreciation & Amortization | 642,500 |
| Net Borrowing | -2.64M |
| Free Cash Flow | -33.87M |
| FCF Per Share | -$0.53 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -123.47% |
| Pretax Margin | -124.77% |
| Profit Margin | -124.77% |
| EBITDA Margin | -119.91% |
| EBIT Margin | -123.47% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -14.47% |
| Shareholder Yield | -14.47% |
| Earnings Yield | -5.92% |
| FCF Yield | -5.51% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $29.50 |
| Price Target Difference | 208.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 37.41% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.91 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |